Right-sided colorectal cancers carried a higher risk of predicted anti-EGFR resistance.
右半结肠癌预测抗EGFR治疗耐药的风险更高。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
Treatment with anti-EGFR agents is used as a potential therapeutic strategy for pancreatic cancer, but the mechanisms are not yet precisely understood.
抗EGFR的药物作为一个有潜力的方案，早已在胰腺癌的治疗中得到使用，但是它的详细机制一直没有得到很好的解释。
Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers.
表皮生长因子受体(EGFR)通路下游基因的激活突变可以引起结直肠癌患者抗egfr耐药。
Comprehensive studies of EGFR polymorphisms in patients with and without severe hypomagnesaemia after treatment with anti-EGFR monoclonal antibodies might shed further light on this toxicity.
采用抗EGFR单克隆抗体治疗后可能伴发或无严重低镁血症，针对患者EGFR多态现象进行广泛研究或许能阐明这种毒副作用的发生机理。
Conclusion: Anweitang may enhance the EGF and EGFR expression in gastric mucosa and reinforce the mucosa's protection function and anti-relapse.
结论：安胃汤可能通过增强胃黏膜egf及EGFR表达，增强胃黏膜保护作用而发挥抗溃疡作用。
Conclusion: Anweitang may enhance the EGF and EGFR expression in gastric mucosa and reinforce the mucosa's protection function and anti-relapse.
结论：安胃汤可能通过增强胃黏膜egf及EGFR表达，增强胃黏膜保护作用而发挥抗溃疡作用。
应用推荐